Bortezomib(Velcade®)-thalidomide-dexamethasone versus thalidomide-dexamethasone to treat multiple myeloma patients progressing or relapsing after autologous transplantation: the MMVAR trial

被引：0
|
作者：
Garderet, L.
Iacobelli, S.
Moreau, P.
Onida, F.
Koenecke, C.
Scheid, C.
Doyen, C.
Bouko, Y.
Ketterer, N.
Masszi, T.
Crawley, C.
Hajek, R.
Linkesch, W.
Ludwig, H.
Harousseau, J. L.
Michallet, M.
de Witte, T.
Niederwieser, D.
Gahrton, G.
Morris, T. C. M.
机构：
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [31] Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone
    Hatjiharissi, E
    Gerotziafas, G
    Hatjileontis, C
    Galaktidou, G
    Bakaloudi, V
    Papaioannou, M
    Kaloutsi, V
    Kortsaris, A
    Christakis, J
    Zervas, K
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, : 402 - 402
  • [32] Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma.
    Dimopoulos, M
    Panayiotidis, P
    Grigoraki, V
    Poziopoulos, C
    Xilouri, I
    Kiamouris, C
    Tassidou, A
    Gika, D
    Stefanoudaki, K
    Anagnostopoulos, N
    Anagnostou, D
    [J]. BLOOD, 2001, 98 (11) : 164A - 164A
  • [33] Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes
    Tacchetti, Paola
    Dozza, Luca
    Di Raimondo, Francesco
    Crippa, Claudia
    Zamagni, Elena
    Bringhen, Sara
    Pantani, Lucia
    Offidani, Massimo
    Montefusco, Vittorio
    Narni, Franco
    Mancuso, Katia
    Cellini, Claudia
    Spadano, Antonio
    Pescosta, Norbert
    Baldini, Luca
    Terragna, Carolina
    Nozzoli, Chiara
    Zambello, Renato
    Derudas, Daniele
    Ballanti, Stelvio
    Cavo, Michele
    [J]. BLOOD, 2018, 132
  • [34] EFFECT OF THALIDOMIDE-DEXAMETHASONE THERAPY ON BONE MARROW ANGIOGENESIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Ladeb, S.
    Mrad, K.
    Abdelkefi, A.
    Torjemane, L.
    Safra, I.
    Hdiji, S.
    Ben Romdhane, N.
    Mdhaffer, M.
    El Omri, H.
    Ben Othman, T.
    Ben Romdhane, K.
    Ben Abdeladhim, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 512 - 512
  • [35] Thalidomide/dexamethasone (TD), bortezomib (Velcade)/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/Velcade as induction therapy prior to high-dose therapy/autologous stem cell transplantation in multiple myeloma
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Oriol, A.
    Terol, M. J.
    Garcia-Larana, J.
    Hernandez, D.
    de la Rubia, J.
    Sureda, A.
    Besalduch, J.
    Palomera, L.
    Gonzalez, Y.
    Echebeste, M. A.
    Diaz-Mediavilla, J.
    de Arriba, F.
    Alegre, A.
    Hernandez, M.
    Lahuerta, J. J.
    Miguel, J. F. San
    Blade, J.
    [J]. BONE MARROW TRANSPLANTATION, 2010, 45 : S18 - S18
  • [36] Superiority of the thalidomide-dexamethasone combination on the VAD in the first line before autograft in the multiple myeloma
    Moreau, Anne-Sophie
    [J]. HEMATOLOGIE, 2005, 11 (05): : 303 - 304
  • [37] Superiority of first-line thalidomide-dexamethasone over vincristine-doxorubicin-dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
    Cavo, M
    Tacchetti, P
    Zamagni, E
    Tosi, P
    Cangini, D
    Cellini, C
    Testoni, N
    de Vivo, A
    Perrone, G
    Tura, S
    Baccarani, M
    [J]. BLOOD, 2004, 104 (11) : 416A - 416A
  • [38] Thalidomide-dexamethasone versus Interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study
    Offidani, Massimo
    Corvatta, Laura
    Polloni, Claudia
    Piersantelli, Maria-Novella
    Gentili, Silvia
    Galieni, Piero
    Visani, Giuseppe
    Alesiani, Francesco
    Catarini, Massimo
    Brunori, Marino
    Samori, Arduino
    Burattini, Maurizio
    Centurioni, Riccardo
    Ferranti, Mario
    Giuliodori, Luciano
    Candela, Marco
    Mele, Anna
    Marconi, Monica
    Leoni, Pietro
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (05) : 653 - 659
  • [39] Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
    Cavo, Michele
    Pantani, Lucia
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Galli, Monica
    Di Raimondo, Francesco
    Rossi, Giuseppe
    Palumbo, Antonio
    Tacchetti, Paola
    Offidani, Massimo
    Montefusco, Vittorio
    Narni, Franco
    Spadano, Tonino
    Cellini, Claudia
    Pescosta, Norbert
    Baldini, Luca
    Ledda, Antonio
    Di Toritto, Tommaso Caravita
    Pezzi, Annalisa
    Falcone, Antonietta
    Nozzoli, Chiara
    Zambello, Renato
    Masini, Luciano
    Gherlinzoni, Filippo
    Petti, Maria Concetta
    Derudas, Daniele
    Ballanti, Stelvio
    De Stefano, Valerio
    Baccarani, Michele
    [J]. BLOOD, 2011, 118 (21) : 816 - 816
  • [40] BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A.
    Pallotti, M.
    Pantani, L.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 265 - 265
12345